Notice of General Meeting and Strategic Review

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Evocutis plc

("Evocutis" or "the Company")

Notice of General Meeting

Strategic Review and Termination of Formal Sale Process

Evocutis plc (AIM: EVO), the company focused on advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, today gives notice of a General Meeting of the members of the Company which will be held at 2 p.m. on Monday, 28 October 2013 at the offices of Walker Morris LLP, Kings Court, 12 King Street, Leeds, LS1 2HL. The General Meeting has been convened to consider in accordance with section 656 of the Companies Act 2006 whether any, and if so, what steps should be taken to manage the situation that the net assets of the Company are less than half its called up share capital.

The Company also announces that it continues to evaluate a number of strategic options open to the Company to maximise value for shareholders, but that it is no longer in discussions with potential offerors in relation to a merger with a third party or a sale of the Company.

The Board has therefore decided to terminate the "Formal Sale Process" as defined in The City Code on Takeovers and Mergers (the "Code"), the commencement of which was announced on 3 December 2012, with immediate effect. As a consequence, the Company is no longer deemed to be in an "Offer Period" as defined in the Code.  The Formal Sales Process has enabled the Company to approach a number of parties on a confidential basis and has led to a number of potential strategic alliances being identified. The Board continues to review these opportunities to derive value from the Company's Labskin™ technology and is in talks with interested parties with a view to establishing potential strategic and trading relationships. The Company will provide a further update to the market as appropriate.

-Ends-

For further information, please contact:

Media enquiries: